102 related articles for article (PubMed ID: 3034846)
1. WF-10129, a novel angiotensin converting enzyme inhibitor produced by a fungus, Doratomyces putredinis.
Ando T; Okada S; Uchida I; Hemmi K; Nishikawa M; Tsurumi Y; Fujie A; Yoshida K; Okuhara M
J Antibiot (Tokyo); 1987 Apr; 40(4):468-75. PubMed ID: 3034846
[TBL] [Abstract][Full Text] [Related]
2. WF-2421, a new aldose reductase inhibitor produced from a fungus, Humicola grisea.
Nishikawa M; Tsurumi Y; Murai H; Yoshida K; Okamoto M; Takase S; Tanaka H; Hirota H; Hashimoto M; Kohsaka M
J Antibiot (Tokyo); 1991 Feb; 44(2):130-5. PubMed ID: 1901310
[TBL] [Abstract][Full Text] [Related]
3. K-26, a novel inhibitor of angiotensin I converting enzyme produced by an actinomycete K-26.
Yamato M; Koguchi T; Okachi R; Yamada K; Nakayama K; Kase H; Karasawa A; Shuto K
J Antibiot (Tokyo); 1986 Jan; 39(1):44-52. PubMed ID: 3005218
[TBL] [Abstract][Full Text] [Related]
4. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
Fink CA; Carlson JE; McTaggart PA; Qiao Y; Webb R; Chatelain R; Jeng AY; Trapani AJ
J Med Chem; 1996 Aug; 39(16):3158-68. PubMed ID: 8759637
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin converting enzyme inhibitors: N-substituted D-glutamic acid gamma dipeptides.
Ksander GM; Yuan AM; Diefenbacher CG; Stanton JL
J Med Chem; 1985 Nov; 28(11):1606-11. PubMed ID: 2999395
[TBL] [Abstract][Full Text] [Related]
6. K-4, a novel inhibitor of angiotensin I converting enzyme produced by Actinomadura spiculosospora.
Koguchi T; Yamada K; Yamato M; Okachi R; Nakayama K; Kase H
J Antibiot (Tokyo); 1986 Mar; 39(3):364-71. PubMed ID: 3009378
[TBL] [Abstract][Full Text] [Related]
7. New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11.
Fink CA; Qiao Y; Berry CJ; Sakane Y; Ghai RD; Trapani AJ
J Med Chem; 1995 Dec; 38(26):5023-30. PubMed ID: 8544178
[TBL] [Abstract][Full Text] [Related]
8. Relationship between angiotensin I blockade and antihypertensive properties of single doses of MK-421 and captopril in spontaneous and renal hypertensive rats.
Sweet CS; Arbegast PT; Gaul SL; Blaine EH; Gross DM
Eur J Pharmacol; 1981 Dec; 76(2-3):167-76. PubMed ID: 6174351
[TBL] [Abstract][Full Text] [Related]
9. Purification and identification of an angiotensin I-converting enzyme inhibitor from soy sauce.
Kinoshita E; Yamakoshi J; Kikuchi M
Biosci Biotechnol Biochem; 1993 Jul; 57(7):1107-10. PubMed ID: 7763982
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive effects of CI-907 (indolapril): a novel nonsulfhydryl angiotensin converting enzyme inhibitor.
Ryan MJ; Boucher DM; Cohen DM; Essenburg AD; Major TC; Mertz TE; Olszewski BJ; Randolph AE; Singer RM; Kaplan HR
J Pharmacol Exp Ther; 1984 Feb; 228(2):312-8. PubMed ID: 6319675
[TBL] [Abstract][Full Text] [Related]
11. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of the converting enzyme inhibitor, enalapril maleate (MK-421).
Sweet CS
Fed Proc; 1983 Feb; 42(2):167-70. PubMed ID: 6295819
[TBL] [Abstract][Full Text] [Related]
13. [Synthesis and biological activity of some Val(Ala)-Tyr and Val-Tyr-Tyr peptides].
Chen PL; Peng SX; Yang ZX
Yao Xue Xue Bao; 1992; 27(12):895-902. PubMed ID: 1299138
[TBL] [Abstract][Full Text] [Related]
14. Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.
Fournie-Zaluski MC; Coric P; Thery V; Gonzalez W; Meudal H; Turcaud S; Michel JB; Roques BP
J Med Chem; 1996 Jun; 39(13):2594-608. PubMed ID: 8691458
[TBL] [Abstract][Full Text] [Related]
15. Studies on angiotensin converting enzyme inhibitors. 4. Synthesis and angiotensin converting enzyme inhibitory activities of 3-acyl-1-alkyl-2-oxoimidazolidine-4-carboxylic acid derivatives.
Hayashi K; Nunami K; Kato J; Yoneda N; Kubo M; Ochiai T; Ishida R
J Med Chem; 1989 Feb; 32(2):289-97. PubMed ID: 2913292
[TBL] [Abstract][Full Text] [Related]
16. Effect of enalapril (MK-421), an orally active angiotensin I converting enzyme inhibitor, on blood pressure, active and inactive plasma renin, urinary prostaglandin E2, and kallikrein excretion in conscious rats.
Schiffrin EL; Gutkowska J; Thibault G; Genest J
Can J Physiol Pharmacol; 1984 Jan; 62(1):116-23. PubMed ID: 6143602
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of pressor responses to intracerebroventricular angiotensin I by angiotensin converting enzyme inhibitors and their effects on systemic blood pressure in conscious rats.
Baum T; Becker FT; Sybertz EJ
Life Sci; 1983 Mar; 32(12):1297-303. PubMed ID: 6300578
[TBL] [Abstract][Full Text] [Related]
18. (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme (ACE). 1. Discovery of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L -proline a novel orally active inhibitor of ACE.
Karanewsky DS; Badia MC; Cushman DW; DeForrest JM; Dejneka T; Loots MJ; Perri MG; Petrillo EW; Powell JR
J Med Chem; 1988 Jan; 31(1):204-12. PubMed ID: 3336020
[TBL] [Abstract][Full Text] [Related]
19. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors.
Kaplan HR; Cohen DM; Essenburg AD; Major TC; Mertz TE; Ryan MJ
Fed Proc; 1984 Apr; 43(5):1326-9. PubMed ID: 6323223
[TBL] [Abstract][Full Text] [Related]
20. Derivatives of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline: effect of changes at positions 2 and 5 of the hexanoic acid portion.
Almquist RG; Crase J; Jennings-White C; Meyer RF; Hoefle ML; Smith RD; Essenburg AD; Kaplan HR
J Med Chem; 1982 Nov; 25(11):1292-9. PubMed ID: 6292422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
